GraniteShares 2x Long NBIS Daily ETF (NBIL)
NBIL is a leveraged exchange-traded fund issued by GraniteShares that tracks the Nasdaq Biotechnology Index with a 2x daily multiplier. The fund aims to deliver twice the daily return of the NBIS — amplifying both gains and losses — but this daily reset mechanism creates a mathematical drag when held beyond a few trading sessions. It is explicitly a tactical instrument for near-term positioning, not a buy-and-hold vehicle.
The index and the leverage mechanism
The Nasdaq Biotechnology Index (NBIS) is a market-cap-weighted collection of roughly 100 biotech and pharmaceutical firms listed on Nasdaq. The index weights heavily toward larger, more-established players, but includes names across drug discovery, diagnostics, medical devices, and therapeutics at various development stages. Unlike broad equity indices, NBIS is structurally volatile — clinical trial outcomes, regulatory decisions, and acquisition news can shift the sector sentiment sharply within a day.
GraniteShares achieves the 2x leverage through index futures, equity swaps, and options. At the close of each trading day, the fund rebalances to reset its leverage target for the next session. This daily reset is the core of NBIL’s design: it locks in each day’s directional move at 2x, then starts fresh. That mechanism works cleanly for overnight traders and intraweek positions.
Volatility decay and why hold time matters
Here lies the mathematical trap. Daily rebalancing of leveraged positions creates what is known as volatility decay or leverage decay — a persistent drag on long-term returns in choppy or oscillating markets.
A simplified example: suppose NBIS is at 100, rises 10% to 110, then falls 10% back to 99. The index is down 1%. NBIL, rebalancing daily, gains 20% on day one (100 to 120), then loses 20% on day two (120 to 96). The fund is down 4%, while the underlying index is down 1%. This gap widens as the number of oscillations increases and as volatility spikes. Over a month of typical market chop, leverage decay can erode 5% to 15% of capital, depending on the magnitude of daily swings.
The prospectus warns about this explicitly. It is not a bug — it is the inevitable consequence of compounding daily leverage. Holding NBIL for longer than a few days is almost certainly a mistake for investors with a medium-term thesis; they should hold the unleveraged NBIS benchmark instead.
Sector concentration and swing risk
Biotech is one of the most volatile equity sectors. Companies in the space dedicate 20–35% of revenue to research, face long regulatory timelines, and often have binary outcomes on key approvals. A single clinical trial result can move an individual holding by 20% or 30%. The index reflects this: it swings far more than the broader market.
When you layer 2x leverage onto a volatile sector, the daily price moves become acute. NBIL can swing 10% or more on a single day when biotech sentiment shifts. This is appropriate for traders managing intraday or overnight risk; it is unsuitable for anyone treating the fund as a longer-term sector exposure.
Costs and liquidity
The expense ratio is typically 0.95% to 1.0% annually, higher than the unleveraged biotech ETF, to account for the derivatives overlay and daily rebalancing. Bid-ask spreads are wide — often 0.5% to 1% of the fund price — because volatility and low overall volume make market-making expensive. A trader holding overnight or across a few days will accumulate slippage that reduces net returns.
The trader’s tool, not the investor’s
NBIL exists for traders making directional bets on biotech sentiment over hours or days. It is also used by hedge funds to express leverage into the sector for specific tactical windows. It is not an alternative to holding biotech stocks for a conviction, not a hedge (because daily rebalancing provides no stable downside protection), and not a suitable vehicle for medium-term or long-term allocation. Anyone using NBIL for longer than a trading day or two should ask whether they are using the right instrument.